Five IPOs raised $1.4 billion this week, bringing the year's total up to 50 IPOs raising $15 billion. Set to be the week's largest offerings, two energy companies struggled: Antero Midstream GP broke issue while Liberty postponed. A mortgage REIT and...read more
UroGen Pharma, which is developing gel-based chemotherapies to treat urological cancers, raised $58 million by offering 4.5 million shares at $13, within the range of $12 to $14. . It originally planned to offer 3.5 million shares and raised 29% more in...read more
The IPO market continues to heat up with six deals on the calendar aiming to raise $1.7 billion in the first week of May. They include three biotechs, two energy companies and one mortgage REIT. This April was the busiest month for IPOs in almost two years, and ...read more
UroGen Pharma, which is developing formulations of a chemotherapy to treat urological cancers, announced terms for its IPO on Monday. It also added two underwriters in the filing. Insiders are purchasing $20 million of shares on the offering. The...read more
US IPO Weekly Recap: Biotechs and energy fail to excite in 5-IPO week
Five IPOs raised $1.4 billion this week, bringing the year's total up to 50 IPOs raising $15 billion. Set to be the week's largest offerings, two energy companies struggled: Antero Midstream GP broke issue while Liberty postponed. A mortgage REIT and...read more
UroGen Pharma prices upsized IPO at $13 midpoint
UroGen Pharma, which is developing gel-based chemotherapies to treat urological cancers, raised $58 million by offering 4.5 million shares at $13, within the range of $12 to $14. . It originally planned to offer 3.5 million shares and raised 29% more in...read more
US IPO Week Ahead: May starts strong with 6 IPOs featuring energy and biotech
The IPO market continues to heat up with six deals on the calendar aiming to raise $1.7 billion in the first week of May. They include three biotechs, two energy companies and one mortgage REIT. This April was the busiest month for IPOs in almost two years, and ...read more
Chemotherapy biotech UroGen Pharma sets terms for $45 million IPO
UroGen Pharma, which is developing formulations of a chemotherapy to treat urological cancers, announced terms for its IPO on Monday. It also added two underwriters in the filing. Insiders are purchasing $20 million of shares on the offering. The...read more